NYSE:JNJPharmaceuticals
Johnson And Johnson IBD Trial Wins Contrast With Valuation And Momentum
Johnson & Johnson (NYSE:JNJ) reported positive Phase 2b results for its investigational co antibody therapy JNJ-4804 in highly refractory ulcerative colitis and Crohn's disease.
The company also released positive Phase 3 data for TREMFYA in perianal fistulizing Crohn’s disease, a difficult form of inflammatory bowel disease.
Johnson & Johnson plans to advance JNJ-4804 and related programs into Phase 3 trials to address high unmet needs in inflammatory bowel diseases.
For investors tracking...